ANEBULO PHARMACEUTICALS, INC. Research and Development Expense
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Research and Development Expense of $1.16 million for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $1.16M, a 4.57% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $809.99K, a 38.40% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-06-30 was $1.13M, a 140.80% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-03-31 was $638.32K, a 14.70% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $4.30M, a 21.16% increase from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $3.55M, a 36.63% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $5.60M, a 89.10% increase from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $2.96M, a 30.46% increase from fiscal 2021.
| Period end | Research and Development Expense 2 month | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $1.16M 10-Q · filed 2026-02-12 | $1.97M 10-Q · filed 2026-02-12 | $3.10M derived: sum of 3 quarters · filed 2026-02-12 | $3.74M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-09-30 | $809.99K 10-Q · filed 2025-11-13 | $1.94M derived: sum of 2 quarters · filed 2025-11-13 | $2.57M derived: sum of 3 quarters · filed 2025-11-13 | $3.80M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-06-30 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $1.76M derived: sum of 2 quarters · filed 2025-09-29 | $2.99M derived: sum of 3 quarters · filed 2026-02-12 | $4.30M 10-K · filed 2025-09-29 | |
| 2025-03-31 | $638.32K 10-Q · filed 2025-05-13 | $1.86M derived: sum of 2 quarters · filed 2026-02-12 | $3.17M 10-Q · filed 2025-05-13 | $3.64M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | $1.22M 10-Q · filed 2026-02-12 | $2.54M 10-Q · filed 2026-02-12 | $3.00M derived: sum of 3 quarters · filed 2026-02-12 | $3.75M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | $1.31M 10-Q · filed 2025-11-13 | $1.78M derived: sum of 2 quarters · filed 2025-11-13 | $2.53M derived: sum of 3 quarters · filed 2025-11-13 | $3.59M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $467.71K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $1.22M derived: sum of 2 quarters · filed 2025-09-29 | $2.28M derived: sum of 3 quarters · filed 2025-09-29 | $3.55M 10-K · filed 2025-09-29 | |
| 2024-03-31 | $748.34K 10-Q · filed 2025-05-13 | $1.81M derived: sum of 2 quarters · filed 2025-05-13 | $3.08M 10-Q · filed 2025-05-13 | $4.50M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $1.06M 10-Q · filed 2025-02-14 | $2.33M 10-Q · filed 2025-02-14 | $3.75M derived: sum of 3 quarters · filed 2025-02-14 | $4.84M derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | $1.27M 10-Q · filed 2024-11-13 | $2.69M derived: sum of 2 quarters · filed 2024-11-13 | $3.78M derived: sum of 3 quarters · filed 2024-11-13 | $5.65M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | $2.51M derived: sum of 2 quarters · filed 2024-09-25 | $4.38M derived: sum of 3 quarters · filed 2024-09-25 | $5.60M 10-K · filed 2024-09-25 | |
| 2023-03-31 | $1.09M 10-Q · filed 2024-05-15 | $2.96M derived: sum of 2 quarters · filed 2024-05-15 | $4.18M 10-Q · filed 2024-05-15 | $5.30M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $1.87M 10-Q · filed 2024-02-13 | $3.09M 10-Q · filed 2024-02-13 | $4.21M derived: sum of 3 quarters · filed 2024-02-13 | $5.13M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-09-30 | $1.22M 10-Q · filed 2023-11-14 | $2.34M derived: sum of 2 quarters · filed 2023-11-14 | $3.26M derived: sum of 3 quarters · filed 2023-11-14 | $3.47M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | $2.03M derived: sum of 2 quarters · filed 2023-09-22 | $2.25M derived: sum of 3 quarters · filed 2023-09-22 | $2.96M 10-K · filed 2023-09-22 | |
| 2022-03-31 | $915.36K 10-Q · filed 2023-05-11 | $1.13M derived: sum of 2 quarters · filed 2023-05-11 | $1.84M 10-Q · filed 2023-05-11 | $3.65M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $212.94K 10-Q · filed 2023-02-10 | $928.03K 10-Q · filed 2023-02-10 | $2.73M derived: sum of 3 quarters · filed 2023-02-10 | $3.01M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-09-30 | $715.10K 10-Q · filed 2022-11-10 | $2.52M derived: sum of 2 quarters · filed 2022-11-10 | $2.79M derived: sum of 3 quarters · filed 2022-11-10 | $2.96M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | $2.08M derived: sum of 2 quarters · filed 2022-09-09 | $2.25M derived: sum of 3 quarters · filed 2022-09-09 | $2.27M 10-K · filed 2022-09-09 | |
| 2021-03-31 | $273.04K 10-Q · filed 2022-05-11 | $443.02K derived: sum of 2 quarters · filed 2022-05-11 | $463.31K 10-Q · filed 2022-05-11 | ||
| 2020-12-31 | $169.98K 10-Q · filed 2022-02-11 | $190.27K 10-Q · filed 2022-02-11 | |||
| 2020-09-30 | $20.29K 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $150.00K 10-K · filed 2021-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |